Study shows that immunotherapy initiation at the end of life has increased over time
In US, the trend was more frequently seen at very low-volume and nonacademic centers than at high-volume and academic centers
Neoadjuvant chemotherapy does not improve survival in pancreatic cancer
In the NORPACT-1 study, adjuvant FOLFORINOX shows no additional benefit compared to upfront surgery in patients with resectable pancreatic ductal adenocarcinoma
A study reveals new insights into resistance mechanisms to hormonal therapy in breast cancer
ESR1 variants show to be predictive of response to fulvestrant and novel mutations have been identified
Most combinations of cancer drugs have additive, but not synergistic efficacy
A study describes an additivity model that can be used to predict the likelihood of success or failure of combination therapies in phase III trials
TILs show long-term efficacy in melanoma, but predicting treatment response is still a challenge
After proof of efficacy in patients with melanoma in a clinical trial, major efforts are now directed to make the use of TILs easier and safer in clinical practice.
Lenvatinib plus pembrolizumab does not improve outcomes in NSCLC
Certain immunotherapy combinations that are effective in selected solid tumours may not be effective in lung cancer without targetable genetic alterations.
Blocking GDF-15 may be promising to overcome resistance to immunotherapy
A study reports evidence of antitumour activity by combining a GDF-15 neutralising antibody with PD-1 inhibition in cancers that are refractory/relapsed to immune checkpoint inhibitors
Additional data confirm the promise of combination therapies for EGFR-mutated NSCLC
Analysis from MARIPOSA-2 and FLAURA2 trials show a potential change of treatment paradigm in both first- and second-line settings
Targeted therapy shows early promise in EBV-positive nasopharyngeal carcinoma
In an early-phase study, the selective inhibitor nanatinostat was well tolerated with evidence of antitumour activity in combination with antiviral therapy
Adjuvant immunotherapy reduces relapse risk in resected or ablated hepatocellular cancer
Data from the IMbrave050 study show benefits of atezolizumab plus bevacizumab in terms of disease recurrence, but long-term data are needed